Literature DB >> 23913674

Medial prefrontal cortex N-methyl-D-aspartate receptor/nitric oxide/cyclic guanosine monophosphate pathway modulates both tachycardic and bradycardic baroreflex responses.

Nilson C Ferreira-Junior1, Alessandra G Fedoce, Fernando H F Alves, Leonardo B M Resstel.   

Abstract

Neural reflex mechanisms, such as the baroreflex, are involved in regulating cardiovascular system activity. Previous results showed that the ventral portion of the medial prefrontal cortex (vMPFC) is involved in modulation only of the cardiac baroreflex bradycardic component. Moreover, vMPFC N-methyl-D-aspartate (NMDA) receptors modulate the bradycardia baroreflex, but the baroreflex tachycardic component has not been investigated. Furthermore, glutamatergic neurotransmission into the vMPFC is involved in activation of the cardiac sympathetic and parasympathetic nervous system. Finally, it has been demonstrated that glutamatergic neurotransmission into the vMPFC can be modulated by the endocannabinoid system and that activation of the CB1 cannabinoid receptor by anandamide, an endocannabinoid, can decrease both cardiac baroreflex bradycardic and tachycardic responses. Thus, there is the possibility that glutamatergic neurotransmission into the vMPFC does not modulate only the cardiac bradycardic component of the baroreflex. Therefore, the present study investigated whether glutamatergic neurotransmission into the vMPFC modulates both cardiac baroreflex bradycardic and tachycardic responses. We found that vMPFC bilateral microinjection of the NMDA receptor antagonist AP7 (4 nmol/200 nl), of a selective inhibitor of neuronal nitric oxide (NO) synthase N-propyl (0.08 nmol/200 nl), of the NO scavenger carboxy-PTIO (2 nmol/200 nl), or of the NO-sensitive guanylate cyclase ODQ (2 nmol/200 nl) decreased the baroreflex activity in unanesthetized rats. Therefore, our results demonstrate the participation of NMDA receptors, production of NO, and activation of guanylate cyclase in the vMPFC in the modulation of both cardiac baroreflex bradycardic and tachycardic responses.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  autonomic system; baroreflex; glutamate; nitric oxide; prefrontal cortex

Mesh:

Substances:

Year:  2013        PMID: 23913674     DOI: 10.1002/jnr.23248

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  6 in total

1.  Multivariate analysis of subjective responses to d-amphetamine in healthy volunteers finds novel genetic pathway associations.

Authors:  Haley L Yarosh; Shashwath A Meda; Harriet de Wit; Amy B Hart; Godfrey D Pearlson
Journal:  Psychopharmacology (Berl)       Date:  2015-04-07       Impact factor: 4.530

2.  Medial prefrontal cortex TRPV1 and CB1 receptors modulate cardiac baroreflex activity by regulating the NMDA receptor/nitric oxide pathway.

Authors:  Davi C Lagatta; Luciana B Kuntze; Nilson C Ferreira-Junior; Leonardo B M Resstel
Journal:  Pflugers Arch       Date:  2018-05-29       Impact factor: 3.657

3.  Glutamatergic, GABAergic, and endocannabinoid neurotransmissions within the dorsal hippocampus modulate the cardiac baroreflex function in rats.

Authors:  Nilson Carlos Ferreira-Junior; Davi Campos Lagatta; Leonardo Barbosa Moraes Resstel
Journal:  Pflugers Arch       Date:  2017-11-15       Impact factor: 3.657

Review 4.  New insights into the role of soluble guanylate cyclase in blood pressure regulation.

Authors:  Emmanuel Buys; Patrick Sips
Journal:  Curr Opin Nephrol Hypertens       Date:  2014-03       Impact factor: 2.894

5.  Medial prefrontal cortex TRPV1 channels modulate the baroreflex cardiac activity in rats.

Authors:  D C Lagatta; N C Ferreira-Junior; L B M Resstel
Journal:  Br J Pharmacol       Date:  2015-11-04       Impact factor: 8.739

6.  Ventromedial prefrontal cortex CRF1 receptors modulate the tachycardic activity of baroreflex.

Authors:  João P T Brufatto; Davi C Lagatta; Daniela L Uliana; Egidi M S Firmino; Anna B Borges-Assis; Leonardo B M Resstel
Journal:  Pflugers Arch       Date:  2021-04-11       Impact factor: 3.657

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.